GenFleet Tightens Board Nomination Rules to Strengthen Governance

An update from Genfleet Therapeutics (Shanghai), Inc. Class H ( (HK:2595) ) is now available.

GenFleet Therapeutics has revised and adopted updated terms of reference for its Board Nomination Committee, effective 24 March 2026, to better regulate the appointment of directors and senior management and optimize board composition. The Nomination Committee, composed mainly of independent non-executive directors and including at least one director of a different gender, is tasked with overseeing board structure, succession planning, independence assessments and diversity policy, with its recommendations submitted to the full Board, underscoring the company’s focus on strengthened governance and regulatory compliance.

The committee’s responsibilities now explicitly cover annual reviews of board size and skills, formulation of director selection criteria and procedures, evaluation of directors’ time commitments and contributions, and support for regular board performance assessments. It is also empowered to seek independent professional advice at the company’s expense, signaling a move toward more rigorous, transparent oversight that could bolster investor confidence and align the company more closely with evolving corporate governance standards in Hong Kong’s capital markets.

More about Genfleet Therapeutics (Shanghai), Inc. Class H

GenFleet Therapeutics (Shanghai), Inc. is a China-based biopharmaceutical company listed in Hong Kong that operates in the life sciences sector. The company focuses on innovative therapeutics and relies on a formal board and committee structure to oversee the nomination and appointment of directors and senior management in line with Hong Kong listing rules and Chinese corporate law.

Average Trading Volume: 1,619,374

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$10.31B

Learn more about 2595 stock on TipRanks’ Stock Analysis page.